Company intelligence / Profile preview

Neomabs

Montreal, Quebec, Canadaneoma-bs.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Developing therapeutic antibodies against novel targets (neoantigens) for acute pediatric leukemia. The company uses high-performance proteomics, immunopeptidomics and computational mass spectrometry methods coupled with a unique biobank of leukemia specimens.

Therapeutic areas: Oncology
Modalities: Therapeutic antibodiesfully human antibodies
Industry: Biotech

Partnerships

TheodorusFonds d'investissement EurêkaCQDMImmune BiosolutionsCHU Sainte-Justine Research CentreAxelys

Beyond the preview

Go deeper on Neomabs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neomabs.

Explore the full profile